Back

Discussion - Cardiac contractility modulation (CCM) in HFrEF NYHA Class III patients.

27 May 2019 (09:10 - 09:15)
Organised by:
Congress Presentation Part of: Late breaking trial III - Innovative and device therapy Device Therapy HFA Premium Access Heart Failure 2019

11 More presentations in this session

Presentation thumbnail
Reduction of Mitral Regurgitation in Patients with Heart Failure and Secondary Mitral Regurgitation: Relationship Between Baseline Biomarkers and Outcomes from the COAPT Trial
Professor W. Abraham (Columbus, US)
Slides Video
Presentation thumbnail
Discussion - COAPT.
Video
Presentation thumbnail
A first in human multi-center, open label, prospective study to evaluate the safety, usability and performance of the V-LAP system
Professor W. Abraham (Columbus, US)
Slides
Presentation thumbnail
Discussion - A first in human multi-center, open label, prospective study to evaluate the safety, usability and performance of the V-LAP system.
Video
Presentation thumbnail
Cardiac contractility modulation (CCM) in HFrEF NYHA Class III patients
Professor D. Burkhoff (New York, US)
Slides Video

Access the full session

Session thumbnail
Late breaking trial III - Innovative and device therapy

The Event

Event poster

Heart Failure 2019

27 May 2019 09:10 CET
You may be interested in
thumbnail
Congress Session
Latest advances in cardiac contractility modulation therapy: a new paradigm in heart failure management
30 March 2025
thumbnail
Congress Session
Debate on primary prevention in ICD therapy
30 March 2025
thumbnail
Congress Session
Optimizing echocardiographic and CMR assessment in the diagnosis and management of hypertrophic cardiomyopathy
12 May 2023
thumbnail
ESC TV Today
Episode 17: Coronary sinus reducer - Best strategies to reach LDL cholesterol goals
5 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources